27 August 2008: NorDiag ASA has entered into a Market Making Agreement with Orion Securities AS for the company's shares which is listed on Oslo Stock Exchange. The purpose of the agreement is to increase the turnover of the shares of NorDiag ASA. The Agreement is in accordance with the standard requirements of Oslo Stock Exchange. The Market Making Agreement will take effect as of today, August 27 2008.

Contact: CFO Tone Kvåle, phone +47 915 19576.

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the notice in Norwegian here